Physician profile
Christopher D'Alterio
NPI 1730165408
$2,659.50
in general payments reported to CMS, 2019-2025
19 companies · $1,037 in 2025
The $1,037 reported for 2025 was more than what 91% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $110 · 2021: $93.43 · 2022: $426 · 2023: $312 · 2024: $454 · 2025: $1,037.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,802.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $489.24 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Alcon Vision LLC | $407.08 | 2019-2025 | Rocklatan, Rhopressa, Tryptyr |
| Tarsus Pharmaceuticals, INC. | $405.93 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $372.03 | 2022-2025 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $211.12 | 2019-2025 | Cequa |
| Abbvie INC. | $173.29 | 2022-2025 | Durysta, Lumigan |
| Johnson & Johnson Surgical Vision, INC. | $146.46 | 2019-2022 | |
| Allergan, INC. | $137.09 | 2019-2021 | |
| Dompe US, INC. | $67.01 | 2022-2024 | Oxervate |
| Novartis Pharmaceuticals Corporation | $59.39 | 2019-2023 | |
| Harrow Eye, LLC | $34.00 | 2024 | Vevye |
| Apellis Pharmaceuticals, INC. | $31.18 | 2025 | Syfovre |
| Biotissue Holdings INC. | $23.79 | 2021 | |
| Coopervision INC. | $20.75 | 2023 | Myday Contact Lens |
| Shire North American Group INC | $18.97 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $17.74 | 2023 | Acthar |
| Astellas Pharma US INC | $15.03 | 2025 | Izervay |
| Menicon America INC | $14.88 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $14.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher D'Alterio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.